Recruiting × Neoplasms, Germ Cell and Embryonal × Clear all NYMC195
Phase 1 Recruiting
30 enrolled
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Phase 1 Recruiting
48 enrolled
A Study of ZW251 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Recruiting
2,000 enrolled
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Phase 1 Recruiting
24 enrolled
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Phase 1 Recruiting
90 enrolled
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Phase 1/2 Recruiting
65 enrolled
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Phase 3 Recruiting
1,780 enrolled
TRIDENT-1
Phase 1/2 Recruiting
500 enrolled 5 FDA
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase 1/2 Recruiting
80 enrolled
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Phase 1 Recruiting
282 enrolled
Germ Cell Tumor and Testicular Tumor DNA Registry
Recruiting
1,000 enrolled
PRESERVE
Phase NA Recruiting
80 enrolled
ASPIRE
Phase 2 Recruiting
35 enrolled
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Recruiting
1,650 enrolled
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Phase 1/2 Recruiting
38 enrolled
SONOKID
Phase 1 Recruiting
24 enrolled
Molecular Epidemiology of Pediatric Germ Cell Tumors
Recruiting
1,151 enrolled
Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
Phase 2 Recruiting
40 enrolled
RAISN
Phase NA Recruiting
44 enrolled
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
Phase 1 Recruiting
37 enrolled
DACT-GCT
Phase 2 Recruiting
33 enrolled
GERMAN
Phase 2 Recruiting
25 enrolled
P3BEP
Phase 3 Recruiting
500 enrolled
GIG-T
Phase 3 Recruiting
387 enrolled
Rare Embryonal Tumors of the Central Nervous System: International Registry
Recruiting
300 enrolled
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
Phase 2 Recruiting
64 enrolled
GD2-CAR T Cells for Pediatric Brain Tumours
Phase 1 Recruiting
54 enrolled
HGT-QoL
Phase NA Recruiting
180 enrolled
MTDPUMCH
Recruiting
2,000 enrolled
GRIPP
Recruiting
400 enrolled
SEPTRALU
Recruiting
5,000 enrolled
Multidisciplinary Approach to Fatigue
Phase NA Recruiting
50 enrolled